Brief: Hyloris Announces Further Extension Of Maxigesic IV Footprint
21/09/2021 06:37
Sept 21 (Reuters) - Hyloris Pharmaceuticals SA HYL.BR :
* REG-HYLORIS ANNOUNCES FURTHER EXTENSION OF MAXIGESIC® IV
FOOTPRINT
* REGULATORY APPROVALS IN SOUTH KOREA, FOURTH LARGEST PHARMA
MARKET IN ASIA, AND PANAMA
Source text for Eikon: ID:nGNE63Txtz
Further company coverage: HYL.BR
(Gdansk Newsroom)
((gdansk.newsroom@thomsonreuters.com; +48 58 769 66 00;))
Recent news on Hyloris Pharmaceuticals SA
See all newsEurope Research Roundup: Akzo Nobel, MTU Aero Engines, Symrise
Brief: Hyloris Pharmaceuticals Says It Obtains Exclusive License Rights In Europe & Turkey From Arbormed For Its Wilson's Disease Therapy
Brief: Hyloris Announces Partnership With Rosemont Pharmaceuticals For Atomoxetine Oral Solution In The U.S.
Brief: Hyloris Announces Positive Study Results For Dofetilide IV
Brief: Hyloris Pharmaceuticals SA Says HY 2024 Revenues (Royalties And Milestones) Increased To EUR 4,2 Million